Structure Therapeutics Q3 loss widens to $65.7 mln

Structure Therapeutics

06/11/2025 21:41

Overview

Structure Therapeutics reports Q3 net loss of $65.7 mln, compared to $34 mln in 2024

Company maintains strong cash position of $799 mln, funding operations through 2027

Phase 1 study for oral amylin receptor agonist ACCG-2671 to start by year-end 2025

Outlook

Structure Therapeutics expects topline data from ACCESS studies by year-end 2025

Company plans to initiate Phase 1 study of ACCG-2671 by year-end 2025

Company expects cash reserves to fund operations through at least 2027

Result Drivers

R&D EXPENSES - Increased R&D expenses driven by clinical trial costs and preclinical research for GLP-1R franchise

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$65.71 mln
Q3 Income From Operations
-$73.79 mln
Q3 Operating Expenses
$73.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Structure Therapeutics Inc is $65.00, about 50.4% above its November 5 closing price of $32.21

Press Release: ID:nGNX9tXbcm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)